Article

Risk factors for non-infectious diarrhea of patients with multiple myeloma after chimeric antigen receptor T- cell immunotherapy: A retrospective observational study

2023-06-30

Abstract excerpt

<h4>Aims: </h4> Patients with multiple myeloma after chimeric antigen receptor T-cell immunotherapy suffered from diarrhea. Recurrent diarrhea further conversely decreases nutritional status Methods This study enrolled 88 patients with multiple myeloma who received chimeric antigen receptor T-cell immunotherapy at one tertiary general hospital in China. Participants were categorized into diarrhea subgroup and no...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e9eaa5ba-4c62-5553-82f2-25e9ac92d176
DOI: 10.21203/rs.3.rs-2985897/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Risk factors for non-infectious diarrhea of patients with multiple myeloma after chimeric antigen receptor T- cell immunotherapy: A retrospective observational studyDOI 10.21203/rs.3.rs-2985897/v1Read

Title: Risk factors for non-infectious diarrhea of patients with multiple myeloma after chimeric antigen receptor T-cell immunotherapy: A retrospective observational studySemantic proximity Read

Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?Semantic proximity Read

Symptom Clusters and Quality of Life in Ambulatory Patients With Multiple MyelomaSemantic proximity Read

Malignancy Risk of Immunoglobin G4-related Disease: Evidence From a Large Cohort Multicenter StudySemantic proximity Read

Further modification of the EASIX score through the addition of phosphorous and IL-6 improves prediction of CRS and ICANS after CAR-T therapySemantic proximity Read

Correlation between the NRS-2002 score and PD-1/CTLA-4 levels in patients with CAPSemantic proximity Read

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read

Practical Management of Adverse Events Associated with Bispecific Antibodies for the Treatment of Multiple Myeloma: A Qualitative Interview StudySemantic proximity Read

Association of Serum Calcium Levels With Renal Impairment and All-cause Death in Chinese Patients With Newly Diagnosed Multiple Myeloma: A Cross-sectional, Longitudinal StudySemantic proximity Read

Identifying Determinants of Survival Disparities in Multiple Myeloma Patients Using Electronic Health Record Data.Semantic proximity Read

Reappraisal of a renovated cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascitesSemantic proximity Read

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in MyelomaSemantic proximity Read